中国医药科学Issue(21)：86-87,102,3.
重组人脑利钠肽和硝普钠治疗重度心力衰竭的临床对比分析
Clinical comparative analysis on recombinant human brain natriuretic peptide and sodium nitroprusside in the treatment of severe heart failure
王静 1李伟 1胡军1
作者信息
- 1. 河南省永城市第一人民医院心内科，河南永城476600
- 折叠
摘要
Abstract
Objective To investigate the clinical effect of recombinant human brain natriuretic peptide and sodium nitroprusside in the treatment of severe heart failure. Methods 120 patients with severe heart failure were divided into the treatment group and the control group according to the different treatment methods, each group had 60 cases.All cases were received the basic treatment,and the patients in the control group were treated with sodium nitroprusside treatment,while the patients in the treatment group were treated with recombinant human brain natriuretic peptide treatment. Results After the treatment,there were no death patients in two groups,the total effective rate of the treatment group and the control group was 96.7%, 85.0% respectively,the difference was significant between the two groups (P < 0.05). There was not significant difference in the serum BNP before the treatment between the two groups,while the serum BNP of two groups decreased significantly after the treatment, and the difference was significant between the two groups (P<0.05).The SV,C0 and LVEF values in the treatment group after the treatment were significantly higher than those in the control group,and the differences were statistically significant(P < 0.05). Conclusion Compare with sodium nitroprusside,the recombinant human brain natriuretic peptide in the treatment of severe heart failure can help to improve the therapeutic effect and improve the heart function of patients, and it's mechanism may related to reduce the natriuretic peptide.关键词
重组人脑利钠肽/重度心力衰竭/硝普钠/心功能状态Key words
Recombinant human brain natriuretic peptide/Severe heart failure/Sodium nitroprusside/Heart function分类
医药卫生引用本文复制引用
王静,李伟,胡军..重组人脑利钠肽和硝普钠治疗重度心力衰竭的临床对比分析[J].中国医药科学,2013,(21):86-87,102,3.
